Viridicatol

Synonyms: 纯绿青霉醇
Viridicatol 是一种喹诺酮类生物碱,具有抗炎、抗菌、抗真菌、促成骨及促软骨形成等活性,可通过降低 ERK、JNK、p38 和 STAT6 的磷酸化水平,抑制 MMP-2、MMP-9、NF-κB 信号通路及 PTP1B,下调肥大细胞活化相关基因,并结合 SHN3 以激活 Wnt/SHN3 信号通路,从而抑制促炎介质及细胞因子的表达并促成骨/软骨分化,可用于纤维肉瘤、过敏、细菌感染、真菌感染及骨质疏松症相关研究。
产品编号: MS-R74665 纯度: 99.93% CAS No.: 14484-44-7 分子式: C15H11NO3 分子量: 253.25
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
3-5 天
50mg
询价
3-5 天
100mg
询价
询价
200mg
询价
询价
500mg
询价
询价

产品描述

Viridicatol 是一种喹诺酮类生物碱,具有抗炎、抗菌、抗真菌、促成骨及促软骨形成等活性,可通过降低 ERK、JNK、p38 和 STAT6 的磷酸化水平,抑制 MMP-2、MMP-9、NF-κB 信号通路及 PTP1B,下调肥大细胞活化相关基因,并结合 SHN3 以激活 Wnt/SHN3 信号通路,从而抑制促炎介质及细胞因子的表达并促成骨/软骨分化,可用于纤维肉瘤、过敏、细菌感染、真菌感染及骨质疏松症相关研究。

生物实验数据

生物活性 Viridicatol is a quinolone alkaloid possessing anti-inflammatory, antibacterial, antifungal, osteogenic, and chondrogenic activities that reduces the phosphorylation levels of ERK, JNK, p38, and STAT6, inhibits MMP-2, MMP-9, the NF-κB signaling pathway, and PTP1B, downregulates mast cell activation-related genes, and binds SHN3 to activate the Wnt/SHN3 signaling pathway, thereby suppressing the expression of pro-inflammatory mediators and cytokines and promoting osteogenic/chondrogenic differentiation, and can be used in research related to fibrosarcoma, allergy, bacterial infection, fungal infection, and osteoporosis.
IC50 & Target S. aureus:15.6 μg/mL(MIC)
体外研究
(In Vitro)

Viridicatol (10-100 μM; 24 h) 对 HT1080 人纤维肉瘤细胞在 10、20 和 50 μM 浓度下无细胞毒性,但在 100 μM 浓度下可诱导细胞毒性。
Viridicatol (10-50 μM; 1 h pre-incubation, followed by 24 h PMA stimulation) 抑制 HT1080 人纤维肉瘤细胞中 PMA 诱导的 MMP-2 和 MMP-9 酶活性。
Viridicatol (10-50 μM; 1 h pre-incubation, followed by 24 h PMA stimulation) 可降低 HT1080 人纤维肉瘤细胞中 PMA 诱导的 MMP-2 蛋白表达,但不影响 MMP-9 蛋白表达。
Viridicatol (10-50 μM; 1 h pre-incubation, followed by 24 h PMA stimulation) 抑制 HT1080 人纤维肉瘤细胞中 PMA 诱导的 ERK、JNK 和 p38 磷酸化。
Viridicatol (10 μg/mL; 1 h pre-incubation prior to 1 h DNP-BSA stimulation) 可在 IgE 介导激活的 RBL-2H3 细胞中调控 128 个差异表达基因,主要下调肥大细胞激活相关的炎症因子和趋化因子基因。
Viridicatol (10 μg/mL; 1 h pre-incubation prior to 1 h DNP-BSA stimulation) 可显著下调 IgE 介导激活的 RBL-2H3 细胞中肥大细胞活化相关基因 (Tnfα、Ccl2、Jun、Fos、Il4、Ccl7、Il13 及 Socs1) 的表达。
Viridicatol (2.5-10 μg/mL; 1 h pre-incubation prior to 15 min DNP-BSA stimulation) 可剂量依赖性地抑制 IgE 介导激活的 RBL-2H3 细胞中 JNK、ERK、P38 和 STAT6 蛋白的磷酸化,从而抑制 MAPK 和 JAK-STAT 通路的激活。
Viridicatol (compound 2) (0.98-500 μg/mL; 1 day) 对金黄色葡萄球菌 (MIC = 15.6 μg/mL) 表现出强效抗菌活性,对大肠杆菌、铜绿假单胞菌、乳酸链球菌、胶孢炭疽菌和禾谷镰孢菌表现出中等活性。
Viridicatol (0.98-500 μg/mL; 2 days) 对 Alternaria brassicae、Botrytis cinerea 和 Valsa mali 表现出强效抗真菌活性 (MIC = 31.2 μg/mL),对链格孢、玉米大斑病菌、核盘菌、辣椒疫霉和牡丹炭疽表现出中等活性。
Viridicatol (compound 1) (5-160 μM; 24 h) 对 RAW264.7 和 BV2 细胞无细胞毒性。
Viridicatol (10-80 μM; 3 h pre-treatment, followed by 24 h LPS stimulation) 可剂量依赖性地抑制 LPS 刺激的 RAW264.7 细胞中促炎介质的产生及相关蛋白的表达,其中 NO 的 IC50 值为 46.03 μM,PGE2 的 IC50 值为 30.37 μM。
Viridicatol (10-80 μM; 3 h pre-treatment, followed by 24 h LPS stimulation) 可剂量依赖性地抑制 LPS 刺激的 BV2 细胞中促炎介质的产生及相关蛋白的表达,其中 NO 的 IC50 值为 43.03 μM,PGE2 的 IC50 值为 34.20 μM。
Viridicatol (10-80 μM; 3 h pre-treatment, followed by 6 h LPS stimulation) 可差异性抑制 LPS 激活的 RAW264.7 细胞与 BV2 细胞中的炎症基因表达。
Viridicatol (10-80 μM; 3 h pre-treatment, followed by 1 h LPS stimulation) 可通过阻断 IκB-α 的磷酸化/降解、NF-κB p65/p50 的核转位及 NF-κB 的 DNA 结合活性,抑制 LPS 刺激的 RAW264.7 和 BV2 细胞中的 NF-κB 信号通路。
Viridicatol (1-10 μM; 5 days) 可促进 MC3T3-E1 前成骨细胞的早期成骨分化,处理 5 天后碱性磷酸酶活性呈浓度依赖性升高可证明这一点。
Viridicatol (1-20 μM; 21 days) 可促进 MC3T3-E1 成骨前体细胞的晚期成骨矿化,处理 21 天后的 EC50 为 5.204 μM。
Viridicatol (1-20 μM; 14 days) 可促进小鼠骨髓来源间充质干细胞的成骨矿化,处理 14 天后其 EC50 为 4.132 μM。
Viridicatol (1-10 μM; ~21 days) 处理约 21 天后,可呈浓度依赖性促进小鼠骨髓来源间充质干细胞的软骨分化。
Viridicatol (5 μM; 0-48 h, 3 days, 5 days, 8 days) 可时间依赖性地抑制 MC3T3-E1 前成骨细胞中 Hivep3 mRNA 的表达,并上调成骨标记基因 Alpl 和 Bglap 的表达。
Viridicatol (5 μM; 8 days) 可促进野生型小鼠骨髓间充质干细胞的成骨矿化,但该作用依赖于 SHN3 的存在。
Viridicatol (1-10 μM; 5 days) 可通过上调 β-catenin、p-GSK-3β 和 p-ERK1/2 的表达并抑制 SHN3 蛋白表达,激活 MC3T3-E1 前成骨细胞中的 Wnt/SHN3 信号通路。
Viridicatol (1-10 μM; 5 days, 5 μM; 3-8 days) 可上调小鼠骨髓间充质干细胞中骨钙蛋白和 β-catenin 蛋白的表达水平。

Cell Viability Assay

Cell Line: HT1080 human fibrosarcoma cells
Concentration: 10 μM, 20 μM, 50 μM, 100 μM
Incubation Time: 24 h
Result: Showed no obvious cytotoxic effect at 10, 20, and 50 μM.
Caused clear cytotoxicity at 100 μM.

Western Blot Analysis

Cell Line: HT1080 human fibrosarcoma cells
Concentration: 10 μM, 20 μM, 50 μM
Incubation Time: 1 h pre-incubation, followed by 24 h PMA stimulation
Result: Significantly inhibited MMP-2 protein expression in a dose-dependent manner.
Had no inhibitory effect on MMP-9 protein expression in PMA-stimulated cells.\n
Dose-dependently reduced the phosphorylation of ERK, JNK, and p38 in PMA-stimulated cells.
Showed significant inhibition at all tested concentrations for each MAPK subtype.

Real Time qPCR

Cell Line: IgE-mediated activated RBL-2H3 cells
Concentration: 10 μg/mL
Incubation Time: 1 h (pre-incubation prior to 1 h DNP-BSA stimulation)
Result: Significantly down-regulated the mRNA expression levels of Tnfα, Ccl2, Jun, Fos, Il4, Ccl7, Il13, and Socs1.

Western Blot Analysis

Cell Line: IgE-mediated activated RBL-2H3 cells
Concentration: 2.5, 5, 10 μg/mL
Incubation Time: 1 h (pre-incubation prior to 15 min DNP-BSA stimulation)
Result: Dose-dependently reduced the levels of phosphorylated JNK, ERK, P38, and STAT6, while total protein levels of these proteins remained unchanged.
Caused the most significant reduction in JNK and ERK phosphorylation at 10 μg/mL.
Significantly reduced P38 and STAT6 phosphorylation at all tested doses.

Cell Viability Assay

Cell Line: murine macrophage-like RAW264.7 cells, murine immortalized microglial BV2 cells
Concentration: 5, 10, 20, 40, 80, 160 μM
Incubation Time: 24 h
Result: Did not reduce cell viability of RAW264.7 or BV2 cells.
Decreased cell viability of RAW264.7 or BV2 cells relative to untreated controls at 160 μM.

RT-PCR

Cell Line: LPS-stimulated murine macrophage-like RAW264.7 cells
Concentration: 10, 20, 40, 80 μM
Incubation Time: 3 h pre-treatment, followed by 6 h LPS stimulation
Result: Reduced LPS-induced IL-1β, IL-6 and TNF-α mRNA expression dose-dependently.
Significantly inhibited IL-1β, IL-6 and TNF-α mRNA expression at 40 and 80 μM.

Cell Differentiation Assay

Cell Line: mouse bone-derived mesenchymal stem cells (BMSCs)
Concentration: 1, 5, 10 μM
Incubation Time: ~21 days
Result: Induced chondrogenic differentiation of BMSCs in a concentration-dependent manner.
Showed the highest relative Alcian blue staining fold change at 10 μM compared to control groups.

Real Time qPCR

Cell Line: MC3T3-E1 pre-osteoblast cells
Concentration: 5 μM
Incubation Time: 0 h, 6 h, 12 h, 24 h, 48 h, 3 days, 5 days, 8 days
Result: Inhibited Hivep3 (SHN3) mRNA expression in a time-dependent manner over 8 days.
Promoted time-dependent increases in Alpl (early osteogenic marker) and Bglap (late osteogenic marker) mRNA expression.

Western Blot Analysis

Cell Line: MC3T3-E1 pre-osteoblast cells
Concentration: 1, 5, 10 μM
Incubation Time: 5 days
Result: Upregulated β-catenin, p-GSK-3β, and p-ERK1/2 protein levels in a concentration-dependent manner.
Left NF-κB, total ERK1/2, and GSK-3β levels unchanged.
Significantly inhibited SHN3 protein expression.

Immunofluorescence

Cell Line: mouse bone-derived mesenchymal stem cells (BMSCs)
Concentration: 1, 5, 10 μM (5 days); 5 μM (3, 5, 8 days)
Incubation Time: 3 days, 5 days, 8 days
Result: Significantly upregulated OCN and β-catenin protein levels in BMSCs, with 5 μM and 10 μM showing significant increases over control after 5 days.
Showed time-dependent increases in OCN and β-catenin protein levels at 5 μM over 3, 5, and 8 days.
体内研究
(In Vivo)

Viridicatol (5 mg/kg;静脉注射;每日;6 周) 可通过增强成骨细胞活性、提升 BV/TV 及骨小梁数量来刺激骨形成,从而预防去卵巢小鼠的骨丢失。
Viridicatol (5 mg/kg;静脉注射;每 2 天 1 次;共 14 天) 可通过增加骨折部位的骨痂体积、骨量以及软骨和骨组织面积来促进骨折愈合。
Free viridicatol (5 mg/kg;静脉注射;每 2 天 1 次;持续 4 周) 在 Col1a2oim/oim 成骨不全症小鼠模型中仅能轻微缓解骨丢失。
Viridicatol 经骨靶向纳米囊泡给药 (5 mg/kg;静脉注射;每 2 天 1 次;持续 4 周) 可显著减少 Col1a2oim/oim 成骨不全症小鼠模型的自发性骨折并提升骨体积分数。

Animal Model: C57BL/6J (female, 10-week-old, bilateral ovariectomy-induced osteoporosis model)
Dosage: 5 mg/kg
Administration: i.v.; daily; 6 weeks
Result: Increased femur BV/TV and Tb.N versus untreated OVX group.
Increased 5th lumbar spine bone mass via Von Kossa staining.
Elevated MS/BS, MAR and BFR/BS.
Increased Ob.S/BS in 5th lumbar vertebrae and femur without altering N.Oc.S/BS.
Caused no significant weight changes, deaths or organ abnormalities.
Animal Model: C57BL/6J (female, 8-week-old, closed transverse diaphyseal femur fracture model stabilized with an intramedullary needle)
Dosage: 5 mg/kg
Administration: i.v.; every 2 days; 14 days
Result: Significantly increased callus volume and BV/TV at the fracture site by micro-CT.
Increased cartilage and bone areas at the fracture site by Safranin O/Fast Green staining.
Increased Ob.S/BS without affecting osteoclast parameters.
Animal Model: Col1a2oim/oim (male, 4-week-old, osteogenesis imperfecta genetic model)
Dosage: 5 mg/kg
Administration: i.v.; every 2 days; 4 weeks
Result: Showed limited therapeutic effects on severe osteopenic phenotype and spontaneous fracture incidence versus bone-targeted nanovesicle viridicatol, but trended toward improved bone parameters versus PBS control.
Significantly mitigated osteopenic phenotype, reduced spontaneous fractures, and increased femur BV/TV and Ob.S/BS versus PBS, free viridicatol and non-targeted nanovesicle controls.
性状 固体
颜色 White to off-white

化学信息

分子量 253.25
分子式 C15H11NO3
CAS No. 14484-44-7
别名 纯绿青霉醇

储存&溶解度

体内实验配方
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 10 mg/mL (39.49 mM), Solution.
10% DMSO+90% Saline: < 10 mg/mL (39.49 mM), Lower concentrations may be soluble, but exact solubility limit is unknown.
请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 125 mg/mL (493.58 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM3.9487 mL19.7433 mL39.4867 mL98.7167 mL
5 mM0.7897 mL3.9487 mL7.8973 mL19.7433 mL
10 mM0.3949 mL1.9743 mL3.9487 mL9.8717 mL
15 mM0.2632 mL1.3162 mL2.6324 mL6.5811 mL
20 mM0.1974 mL0.9872 mL1.9743 mL4.9358 mL
25 mM0.1579 mL0.7897 mL1.5795 mL3.9487 mL
30 mM0.1316 mL0.6581 mL1.3162 mL3.2906 mL
40 mM0.0987 mL0.4936 mL0.9872 mL2.4679 mL
50 mM0.0790 mL0.3949 mL0.7897 mL1.9743 mL
60 mM0.0658 mL0.3291 mL0.6581 mL1.6453 mL
80 mM0.0494 mL0.2468 mL0.4936 mL1.2340 mL
100 mM0.0395 mL0.1974 mL0.3949 mL0.9872 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础